SEARCH

SEARCH BY CITATION

References

  • Alebouyeh M., Takeda M., Onozato M. L. et al. (2003) Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites. J. Pharmacol. Sci. 93, 430436.
  • Ames B. N., Cathcart R., Schwiers E. and Hochstein P. (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. USA 78, 68586862.
  • Anantharam V., Lehrmann E., Kanthasamy A., Yang Y., Banerjee P., Becker K. G., Freed W. J. and Kanthasamy A. G. (2007) Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson’s disease. Neurochem. Int. 50, 834847.
  • Ascherio A., LeWitt P. A., Xu K. et al. (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66, 14601468.
  • Bahn A., Ljubojevic M., Lorenz H., Schultz C., Ghebremedhin E., Ugele B., Sabolic I., Burckhardt G. and Hagos Y. (2005) Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am. J. Physiol. Cell Physiol. 289, C10751084.
  • Burdett T. C., Desjardins C. A., Logan R., McFarland N. R., Chen X. and Schwarzschild A. M. (2012) Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomed. Chromatogr. Accepted.
  • Cipriani S., Chen X. and Schwarzschild M. A. (2010) Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark. Med. 4, 701712.
  • Cipriani S., Desjardins A. C., Burdett C. T., Xu Y., Xu K. and Schwarzschild A. M. (2012) Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson’s disease. PLoS One, 7, e37331.
  • Crawford Jr G. D., Le W. D., Smith R. G., Xie W. J., Stefani E. and Appel S. H. (1992) A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 12, 33923398.
  • Davies K. J., Sevanian A., Muakkassah-Kelly S. F. and Hochstein P. (1986) Uric acid-iron ion complexes A new aspect of the antioxidant functions of uric acid. Biochem. J. 235, 747754.
  • Du Y., Chen C. P., Tseng C. Y., Eisenberg Y. and Firestein B. L. (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55, 463472.
  • Duan W., Ladenheim B., Cutler R. G., Kruman I. I., Cadet J. L. and Mattson M. P. (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J. Neurochem. 80, 101110.
  • Facheris M. F., Hicks A. A., Minelli C. et al. (2011) Variation in the uric acid transporter gene SLC2A9 and its association with AAO of Parkinson’s disease. J. Mol. Neurosci. 43, 246250.
  • Fujishita K., Ozawa T., Shibata K., Tanabe S., Sato Y., Hisamoto M., Okuda T. and Koizumi S. (2009) Grape seed extract acting on astrocytes reveals neuronal protection against oxidative stress via interleukin-6-mediated mechanisms. Cell. Mol. Neurobiol. 29, 11211129.
  • Guerreiro S., Ponceau A., Toulorge D., Martin E., Alvarez-Fischer D., Hirsch E. C. and Michel P. P. (2009) Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J. Neurochem. 109, 11181128.
  • Haberman F., Tang S. C., Arumugam T. V., Hyun D. H., Yu Q. S., Cutler R. G., Guo Z., Holloway H. W., Greig N. H. and Mattson M. P. (2007) Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neuromolecular Med. 9, 315323.
  • Hansen M. B., Nielsen S. E. and Berg K. (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119, 203210.
  • Hosoyamada M., Ichida K., Enomoto A., Hosoya T. and Endou H. (2004) Function and localization of urate transporter 1 in mouse kidney. J. Am. Soc. Nephrol. 15, 261268.
  • Imamura K., Takeshima T., Nakaso K., Ito S. and Nakashima K. (2008) Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. Neurosci. Lett. 440, 97102.
  • Kono H., Chen C. J., Ontiveros F. and Rock K. L. (2010) Uric acid promotes an acute inflammatory response to sterile cell death in mice. J. Clin. Invest. 120, 19391949.
  • Li X. Z., Bai L. M., Yang Y. P., Luo W. F., Hu W. D., Chen J. P., Mao C. J. and Liu C. F. (2009) Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced inflammation. Neurosci. Res. 65, 252258.
  • Mori S., Takanaga H., Ohtsuki S., Deguchi T., Kang Y. S., Hosoya K. and Terasaki T. (2003) Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J. Cereb. Blood Flow Metab. 23, 432440.
  • Oda M., Satta Y., Takenaka O. and Takahata N. (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol. Biol. Evol. 19, 640653.
  • Ohtsuki S., Kikkawa T., Mori S., Hori S., Takanaga H., Otagiri M. and Terasaki T. (2004) Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J. Pharmacol. Exp. Ther. 309, 12731281.
  • Preitner F., Bonny O., Laverriere A., Rotman S., Firsov D., Da Costa A., Metref S. and Thorens B. (2009) Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc. Natl. Acad. Sci. USA 106, 1550115506.
  • Rappold P. M. and Tieu K. (2010) Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics 7, 413423.
  • Robins E., Smith D. E. and McCaman R. E. (1953) Microdetermination of purine nucleoside phosphorylase activity in brain and its distribution within the monkey cerebellum. J. Biol. Chem. 204, 927937.
  • Ross C. A. and Smith W. W. (2007) Gene-environment interactions in Parkinson’s disease. Parkinsonism Relat. Disord. 13(Suppl 3), S30915.
  • Saura J., Angulo E., Ejarque A. et al. (2005) Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J. Neurochem. 95, 919929.
  • Schwarzschild M. A., Schwid S. R., Marek K. et al. (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch. Neurol. 65, 716723.
  • Sherer T. B., Betarbet R., Stout A. K., Lund S., Baptista M., Panov A. V., Cookson M. R. and Greenamyre J. T. (2002) An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22, 70067015.
  • Shoulson I. (2010) Therapeutic directions for Parkinson’s disease. Mov. Disord. 25(Suppl 1), S1524.
  • Truszkowski R. and Goldmanowna C. (1933) Uricase and its action: distribution in various animals. Biochem. J. 27, 612614.
  • Wang L. J., Luo W. F., Wang H. H., Ni G. H., Ye Y., Li D. and Liu C. F. (2010) Protective effects of uric acid on nigrostriatal system injury induced by 6-hydroxydopamine in rats. Zhonghua Yi Xue Za Zhi 90, 13621365.
  • Weisskopf M. G., O’Reilly E., Chen H., Schwarzschild M. A. and Ascherio A. (2007) Plasma urate and risk of Parkinson’s disease. Am. J. Epidemiol. 166, 561567.
  • Whiteman M., Ketsawatsakul U. and Halliwell B. (2002) A reassessment of the peroxynitrite scavenging activity of uric acid. Ann. N. Y. Acad. Sci. 962, 242259.
  • Xu K., Xu Y. H., Chen J. F. and Schwarzschild M. A. (2010) Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson’s disease. Neuroscience 167, 475481.
  • Yu P. H. and Zuo D. M. (1997) Enhanced tolerance of neuroblastoma cells towards the neurotoxin 6-hydroxydopamine following specific cell-cell interaction with primary astrocytes. Neuroscience 78, 903912.
  • Zhu T. G., Wang X. X., Luo W. F., Zhang Q. L., Huang T. T., Xu X. S. and Liu C. F. (2011) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci. Lett. 506, 175179.